Key Features
Limosilactobacillus reuteri DSM17648 recognizes and binds to surface‑protein structures of Helicobacter pylori to form co‑aggregates. These co‑aggregates are eliminated from the body via the gastrointestinal tract, lowering the H. pylori load in the stomach. Aggregation immobilizes H. pylori and masks its surface binding sites, preventing adhesion to the gastric mucosa.
In‑vitro tests show that co‑aggregation between Limosilactobacillus reuteri DSMZ 17648 and Helicobacter pylori strains occurs within seconds. One single cell of L. reuteri DSMZ 17648 can bind to 2‑3 H. pylori cells. It efficiently co‑aggregates H. pylori in artificial gastric fluid at 37 °C. Co‑aggregation takes place across pH 2‑8, covering gastric pH range from fasting to post‑prandial states, and is not interfered with by common dietary sugars. Pepsin is required for full activation of its aggregation activity. L. reuteri DSMZ 17648 adheres to H. pylori via surface proteins for excretion out of the body, with no known side‑effects.
Numerous clinical trials have demonstrated that Limosilactobacillus reuteri DSMZ 17648 delivers a 54% eradication rate after two‑week monotherapy, and its 8‑week monotherapy effect approaches that of triple‑antibiotic therapy (65%). It enables significant and sustained reduction of H. pylori load in infected subjects with good safety profile, and helps relieve mild dyspepsia symptoms.